Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study

被引：0
|
作者：
Ueshima, Kazuomi
Kudo, Masatoshi
Tsuchiya, Kaoru
Kato, Naoya
Yamashita, Tatsuya
Shimose, Shigeo
Numata, Kazushi
Kodama, Yuzo
Tanaka, Yasuhito
Kuroda, Hidekatsu
Itoh, Shinji
Aikata, Hiroshi
Hiraoka, Atsushi
Moriguchi, Michihisa
Wada, Yoshiyuki
Nakao, Kazuhiko
Tateishi, Ryosuke
Ogasawara, Sadahisa
Yamamoto, Kouji
Ikeda, Masafumi
机构：
[1] Kindai Univ, Fac Med, Osaka, Osaka, Japan
[2] Kindai Univ, Fac Med, Osaka, Japan
[3] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Musashino, Japan
[4] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chuo Ku, Chiba, Japan
[5] Kanazawa Univ Hosp, Kanazawa, Japan
[6] Kurume Univ Hosp, Kurume, Japan
[7] Yokohama City Univ, Med Ctr, Yokohama, Japan
[8] Kobe Univ, Div Gastroenterol, Dept Internal Med, Grad Sch Med, Kobe, Japan
[9] Kumamoto Univ, Dept Gastroenterol & Hepatol, Fac Life Sci, Kumamoto, Japan
[10] Iwate Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Yahaba, Japan
[11] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan
[12] Hiroshima Prefectural Hosp, Dept Gastroenterol, Hiroshima, Japan
[13] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Matsuyama, Japan
[14] Kyoto Prefectural Univ Med, Kyoto, Japan
[15] Natl Hosp Org, Kyushu Med Ctr, Fukuoka, Japan
[16] Nagasaki Univ, Dept Gastroenterol & Hepatol, Grad Sch Biomed Sci, Nagasaki, Japan
[17] Univ Tokyo Hosp, Bunkyo Ku, Tokyo, Japan
[18] Chiba Univ, Grad Sch Med, Chiba, Japan
[19] Yokohama City Univ, Dept Biostat, Sch Med, Yokohama, Japan
[20] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：1
相关论文
共 46 条
  • [21] Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen Lam
    Kurosaki, Masayuki
    Izumi, Namiki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 535 - 535
  • [22] Transarterial Chemoembolization Combined with Lenvatinib Plus Sequential Microwave Ablation for Large Hepatocellular Carcinoma Beyond Up-to-Seven Criteria: A Retrospective Cohort Study
    Tang, Lu
    Hou, Yingwen
    Huang, Zhimei
    Huang, Jinhua
    ACADEMIC RADIOLOGY, 2024, 31 (07) : 2795 - 2806
  • [23] Achievement of Complete Response and Drug-free Status by Atezolizumab Plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-stage Hepatocellular Carcinoma: A Multicenter Proof-of-Concept Study
    Kudo, Masatoshi
    Aoki, Tomoko
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Minami, Yasunori
    Ida, Hiroshi
    Nishida, Naoshi
    Ogawa, Chikara
    Tomonari, Tetsu
    Nakamura, Noriaki
    Kuroda, Hidekatsu
    Takebe, Atsushi
    Takeyama, Yoshifumi
    Hidaka, Masaaki
    Eguchi, Susumu
    Chan, Stephen L.
    Kurosaki, Masayuki
    Izumi, Namiki
    LIVER CANCER, 2023, 12 (04) : 321 - 338
  • [24] NeoTACE: A multicenter, randomized study evaluating the efficacy and safety of neoadjuvant HAIC for TACE plus donafenib in BCLC B stage hepatocellular carcinoma outside of up-to-seven
    Wang, Xiaodong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab-interim analysis of the FAB-HCC phase II pilot study
    Pomej, Katharina
    Frick, Adrian
    Scheiner, Bernhard
    Balcar, Lorenz
    Pajancic, Larissa
    Klotz, Anton
    Regnat, Katharina
    Zinober, Kerstin
    Trauner, Michael
    Tamandl, Dietmar
    Gasche, Christoph
    Pinter, Matthias
    JOURNAL OF HEPATOLOGY, 2024, 80 : S436 - S437
  • [26] Tumor burden in patients with early and intermediate-stage hepatocellular carcinoma undergoing liver resection: a retrospective multicenter study on clinical and oncological outcomes
    Martin, David
    Smet, Heloise
    Costa, Ana Cristina Da Silva
    Halkic, Nermin
    Uldry, Emilie
    Tabrizian, Parissa
    Schwartz, Myron
    Mahamid, Ahmad
    Goumard, Claire
    Scatton, Olivier
    Perinel, Julie
    Adham, Mustapha
    Demartines, Nicolas
    Melloul, Emmanuel
    HPB, 2023, 25 (07) : 836 - 844
  • [27] Transarterial chemoembolization (TACE) with or without lenvatinib (len) plus pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study
    Llovet, J.
    Finn, R. S.
    Ren, Z.
    Guo, Y.
    Han, G.
    Lin, H.
    Zheng, J.
    Ogasawara, S.
    Li, H.
    Kim, J. H.
    Zhao, H.
    Li, C.
    Madoff, D. C.
    Ghobrial, R. M.
    El-Khoueiry, A. B.
    Vogel, A.
    Peng, X.
    Mody, K.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1229 - 1229
  • [28] A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).
    Sangro, Bruno
    Harding, James J.
    Johnson, Matthew
    Palmer, Daniel H.
    Edeline, Julien
    Abou-Alfa, Ghassan K.
    Cheng, Ann-Lii
    Decaens, Thomas
    El-Khoueiry, Anthony B.
    Finn, Richard S.
    Galle, Peter R.
    Park, Joong-Won
    Yau, Thomas
    Begic, Damir
    Shen, Yun
    Neely, Jaclyn
    Sama, Ashwin Reddy
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [29] Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
    Aoki, Tomoko
    Kudo, Masatoshi
    Nishida, Naoshi
    Ueshima, Kazuomi
    Tsuchiya, Kaoru
    Tada, Toshifumi
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Ida, Hiroshi
    Minami, Yasunori
    Kuroda, Hidekatsu
    Nakamura, Noriaki
    Hiraoka, Atsushi
    Tomonari, Tetsu
    Tani, Joji
    Naganuma, Atsushi
    Kakizaki, Satoru
    Ogawa, Chikara
    Hatanaka, Takeshi
    Ishikawa, Toru
    Kawata, Kazuhito
    Takebe, Atsushi
    Matsumoto, Ippei
    Hidaka, Masaaki
    Kurosaki, Masayuki
    Kumada, Takashi
    Izumi, Namiki
    JOURNAL OF GASTROENTEROLOGY, 2025,
  • [30] LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment
    Ogasawara, S.
    Llovet, J.
    El-Khoueiry, A.
    Vogel, A.
    Madoff, D.
    Finn, R.
    Ren, Z.
    Modi, K.
    Li, J.
    Siegel, A.
    Dubrovsky, L.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S124 - S125
12345